Literature DB >> 870181

The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.

M T Scott, L Milas.   

Abstract

Killed Corynebacterium parvum was labeled with fluorescein isothiocyanate or 125I, and both preparations were shown to retain lymphoreticular stimulatory and antitumor activity. Large amounts of C. parvum injected i.v. were found in the liver, spleen, and lungs with less in bone marrow and lymph nodes. Apart from a rapid loss from the lungs within 24 hr, the persistence of killed C. parvum was striking, and some intact bacteria were still detectable in the liver and spleen at 15 days. (By contrast, the breakdown of an inactive C. parvum strain in the liver was considerably faster). The blood clearance of 125I-labeled C. parvum injected i.v. into tumor-bearing mice was more rapid than in normal mice, and the absolute, but not the unit, amounts of C. parvum taken up by the spleen and tumor-draining node were increased. 125I-labeled C. parvum was found within the body of established solid tumor, but there was no correlation between the amounts of C. parvum taken up by various mouse solid tumors after i.v. injection and their susceptibility to i.v. C. parvum therapy. The distribution and persistence of C. parvum injected into a tumor lesion was similar to that after s.c. injection. The bulk of the inoculum was retained at the injection site and draining lymph node. Contralateral nodes were unlabeled, and uptake in the liver and spleen was considerably less than after i.v. injection. Although no C. parvum was found in peritoneal cells after i.v. injection, the macrophages in this population became activated and were capable of nonspecifically inhibiting tumor cell growth in vitro.

Entities:  

Mesh:

Year:  1977        PMID: 870181

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Effects of intravenous injection of two different strains of Corynebacterium parvum in the mouse.

Authors:  T E Sadler; P D Jones; J E Castro; I A Lampert
Journal:  Br J Exp Pathol       Date:  1979-12

2.  Distribution of intrapleural and intravenous Corynebacterium parvum in humans; 99mTc-, and 131I-labeled bacteria.

Authors:  M Kaufmann; J Marqverson; K E Stanley; C Mouritzen; H Hvid-Hansen
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Proceedings of the British Association For Cancer Research, 19th Annual General Meeting St. Edmund Hall, University of Oxford 4--6 April, 1978.

Authors: 
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

4.  Fate of vaccines of Propionibacterium acnes after phagocytosis by murine macrophages.

Authors:  A T Pringle; C S Cummins; B F Bishop; V S Viers
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

5.  Arthropathic properties of cell wall polymers from normal flora bacteria.

Authors:  S A Stimpson; R R Brown; S K Anderle; D G Klapper; R L Clark; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

6.  Genetic control of Propionibacterium acnes-induced protection of mice against Babesia microti.

Authors:  P R Wood; I A Clark
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

7.  Nonspecific resistance to infection expressed within the Peyer's patches of the small intestine.

Authors:  T T MacDonald; M Bashore; P B Carter
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

8.  TLR9-dependent and independent pathways drive activation of the immune system by Propionibacterium acnes.

Authors:  Sandrine Tchaptchet; Marina Gumenscheimer; Christoph Kalis; Nikolaus Freudenberg; Christoph Hölscher; Carsten J Kirschning; Marinus Lamers; Chris Galanos; Marina A Freudenberg
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

9.  Deciphering the intracellular fate of Propionibacterium acnes in macrophages.

Authors:  Natalie Fischer; Tim N Mak; Debika Biswal Shinohara; Karen S Sfanos; Thomas F Meyer; Holger Brüggemann
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

10.  Inhibition by the Landschütz ascites carcinoma of the granulomatous inflammatory response to C. parvum.

Authors:  L C McIntosh; R G Pugh-Humphreys; R A Fraser; A W Thomson
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.